Brief: Crossject Signs Zepizure® Commercialization Agreement For Northern Europe

Crossject SA

22/12/2023 06:47

Dec 22 (Reuters) - Crossject SA  74C.F :
    * CROSSJECT SIGNS ZEPIZURE® COMMERCIALIZATION AGREEMENT FOR
NORTHERN EUROPE
    * AGREEMENT, WITH UNDISCLOSED STRATEGIC PARTNER, ALLOWS
CROSSJECT
TO BENEFIT FROM STRONG EXPERTISE IN FIELD AND PROVIDES IMPETUS
TO COMMERCIAL LAUNCHES
    * WILL RECEIVE MILESTONE PAYMENTS OF UP TO EUR 1 MILLION IN
TOTAL,
UPON MARKETING AUTHORIZATIONS GRANTED IN TERRITORIES
    * WILL SELL ZEPIZURE® WITH A MARKUP THAT IS A SHARE OF GROSS
MARGIN (NET SALES MINUS COST OF GOODS)
    * COVERS REGULATORY DEVELOPMENT COSTS AND OWNS POTENTIAL
MARKETING
AUTHORIZATIONS, WHILE CROSSJECT'S PARTNER CONTROLS AND IS
RESPONSIBLE FOR ALL COMMERCIAL COSTS

Source text for Eikon:  ID:nGNE3gLLsT 
Further company coverage:  74C.F 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))